BCA
TCRT icon

Berman Capital Advisors’s Alaunos Therapeutics TCRT Stock Holding History

Berman Capital Advisors’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$2K Buy
9
+6
+200% +$1.83K ﹤0.01% 1745
2021
Q2 		$1K Buy
+3
New +$1.4K ﹤0.01% 1808

Other funds holding TCRT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Berman Capital Advisors's TCRT Position: Q3 2021 in Review

Berman Capital Advisors increased its Alaunos Therapeutics (TCRT) stake by 200% in Q3 2021, buying an estimated $1.83K and bringing the position to 9 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #1745.

Berman Capital Advisors first reported a position in TCRT in Q2 2021 and has held it in 2 quarters since. 162 funds tracked by Wall St. Rank hold TCRT as of Q3 2021.

  • Berman Capital Advisors held 9 shares of Alaunos Therapeutics worth $2K as of Q3 2021.
  • Berman Capital Advisors bought 6 Alaunos Therapeutics shares in Q3 2021, an estimated $1.83K.
  • Alaunos Therapeutics made up ﹤0.01% of Berman Capital Advisors's portfolio in Q3 2021, its #1745 holding.
  • Berman Capital Advisors first reported a position in Alaunos Therapeutics in Q2 2021 and has held it in 2 quarters since.
  • 162 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q3 2021.

Based on Berman Capital Advisors's 13F filing for Q3 2021, filed 7 Oct 2021.